PF-07872449

PF-07872449 is an investigational pneumococcal conjugate component developed by Pfizer as part of its next-generation, expanded multivalent pneumococcal conjugate vaccine (PCV) program. It is being evaluated in Phase 3 clinical trials (such as EU CTIS 2025-523447-35-02) as one of several additional serotype conjugates intended to be administered alongside or formulated with Prevenar 20 (PCV20). The vaccine component utilizes polysaccharide-protein conjugation technology, where a specific capsular polysaccharide from *Streptococcus pneumoniae* is chemically linked to a carrier protein (typically CRM197). This conjugation is designed to induce a T-cell dependent immune response, which is critical for establishing long-term immunologic memory and efficacy in infants and young children. The expanded vaccine regimen aims to provide broader protection against invasive pneumococcal disease by covering additional serotypes not included in current 13-valent or 20-valent vaccines.